These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38655677)

  • 1. Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.
    Megna M; Ruggiero A; Torta G; Martora F; Bianco M; Potestio L
    Clin Exp Dermatol; 2024 Sep; 49(10):1186-1189. PubMed ID: 38655677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).
    Orsini D; Megna M; Assorgi C; Balato A; Balestri R; Bernardini N; Bettacchi A; Bianchelli T; Bianchi L; Buggiani G; Burlando M; Brunasso A; Caldarola G; Cameli N; Campanati A; Campione E; Carugno A; Chersi K; Conti A; Costanzo A; Cozzani E; Cuccia A; D'Amico D; Dal Bello G; Dall'Olio EG; Dapavo P; De Simone C; Di Brizzi EV; Di Cesare A; Dini V; Esposito M; Errichetti E; Fargnoli MC; Fiorella CS; Foti A; Fratton Z; Gaiani FM; Gisondi P; Giuffrida R; Giunta A; Guarneri C; Legori A; Loconsole F; Malagoli P; Narcisi A; Paolinelli M; Potestio L; Prignano F; Rech G; Rossi A; Skroza N; Trovato F; Venturini M; Richetta AG; Pellacani G; Dattola A
    J Dermatolog Treat; 2024 Dec; 35(1):2393376. PubMed ID: 39164008
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
    Rompoti N; Stefanaki I; Panagakis P; Vavouli C; Politou M; Papoutsaki M; Befon A; Koutsa F; Lazou E; Koumprentziotis IA; Chasapi V; Stratigos A; Nicolaidou E
    Arch Dermatol Res; 2024 Apr; 316(5):133. PubMed ID: 38662223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.
    van Lümig PP; van de Kerkhof PC; Boezeman JB; Driessen RJ; de Jong EM
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):593-600. PubMed ID: 22416818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
    Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
    Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
    Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
    Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
    Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
    Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ixekizumab in a Real-Life Practice: A Retrospective Bicentric Study.
    Magdaleno-Tapial J; Carmena-Ramón R; Valenzuela-Oñate C; Ortiz-Salvador JM; Sabater-Abad J; Hernández-Bel P; Gimeno-Carpio E; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):585-589. PubMed ID: 31006480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.